

## AngioDynamics Selected as a Founding Member of New NASDAQ Health Care Index

QUEENSBURY, N.Y.--(BUSINESS WIRE)--July 29, 2005--AngioDynamics, Inc. (Nasdaq:ANGO) today announced that it has been chosen to be a founding member of the new NASDAQ Health Care Index(sm) (Symbol:IXHC) and that its common shares have been added to this index. The index, comprised of 542 companies, was launched on July 12, 2005.

The NASDAQ Health Care Index is a market value weighted index that contains NASDAQ-listed companies which are classified according to the FTSE Global Classification System as "Health," "Pharmaceutical" or "Biotechnology." They include health maintenance organizations, hospital management and long-term care, medical equipment and supplies, other healthcare, biotechnology and pharmaceutical companies.

"We are very pleased that investors interested in the health care sector will gain exposure to AngioDynamics through this index," commented Eamonn P. Hobbs, CEO of AngioDynamics.

### About AngioDynamics

AngioDynamics, Inc. ([www.angiodynamics.com](http://www.angiodynamics.com)) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic catheters, hemodialysis catheters, endovascular laser venous system products, PTA dilation balloon catheters, image-guided vascular access products, thrombolytic products and drainage products.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, and competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Form 10-Q for the quarter ended February 26, 2005, and its Annual Report on Form 10-K for the year ended May 29, 2004, may affect the actual results achieved by the Company.

CONTACT: Company Contact:  
AngioDynamics, Inc.  
Joe Gerardi, 800-772-6446 x115  
[www.angiodynamics.com](http://www.angiodynamics.com)  
or  
Investor Relations Contacts:  
Lippert/Heilshorn & Associates, Inc.  
Kim Sutton Golodetz, 212-838-3777  
[kgolodetz@lhai.com](mailto:kgolodetz@lhai.com)  
or  
Bruce Voss, 310-691-7100  
[bvoss@lhai.com](mailto:bvoss@lhai.com)

SOURCE: AngioDynamics, Inc.